L.C.E. SANDOZ 200/50/200 levodopa 200 mg, carbidopa (as carbidopa monohydrate) 50 mg and entacapone 200 mg film-coated tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 200/50/200 levodopa 200 mg, carbidopa (as carbidopa monohydrate) 50 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); levodopa, quantity: 200 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: mannitol; titanium dioxide; sucrose; magnesium stearate; croscarmellose sodium; glycerol; povidone; iron oxide red; maize starch; hypromellose; polysorbate 80 - l.c.e. sandoz 200/50/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 150/37.5/200 levodopa 150 mg, carbidopa (as carbidopa monohydrate) 37.5 mg and entacapone 200 mg film-coated tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 150/37.5/200 levodopa 150 mg, carbidopa (as carbidopa monohydrate) 37.5 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg); entacapone, quantity: 200 mg; levodopa, quantity: 150 mg - tablet, film coated - excipient ingredients: iron oxide yellow; croscarmellose sodium; povidone; magnesium stearate; polysorbate 80; glycerol; sucrose; iron oxide red; hypromellose; mannitol; titanium dioxide; maize starch - l.c.e. sandoz 150/37.5/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 125/31.25/200 levodopa 125 mg, carbidopa (as carbidopa monohydrate) 31.25 mg and entacapone 200 mg film-coated tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 125/31.25/200 levodopa 125 mg, carbidopa (as carbidopa monohydrate) 31.25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 33.8 mg (equivalent: carbidopa, qty 31.25 mg); levodopa, quantity: 125 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: glycerol; titanium dioxide; croscarmellose sodium; sucrose; magnesium stearate; polysorbate 80; mannitol; maize starch; povidone; iron oxide red; hypromellose - l.c.e. sandoz 125/31.25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 100/25/200 levodopa 100 mg, carbidopa (as carbidopa monohydrate) 25 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg); levodopa, quantity: 100 mg; entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: povidone; iron oxide yellow; croscarmellose sodium; mannitol; glycerol; maize starch; titanium dioxide; magnesium stearate; polysorbate 80; hypromellose; sucrose; iron oxide red - l.c.e. sandoz 100/25/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

L.C.E. SANDOZ 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

l.c.e. sandoz 75/18.75/200 levodopa 75 mg, carbidopa (as carbidopa monohydrate) 18.75 mg and entacapone 200 mg film-coated tablet bottle

sandoz pty ltd - carbidopa monohydrate, quantity: 20.25 mg (equivalent: carbidopa, qty 18.75 mg); entacapone, quantity: 200 mg; levodopa, quantity: 75 mg - tablet, film coated - excipient ingredients: polysorbate 80; maize starch; hypromellose; croscarmellose sodium; iron oxide red; titanium dioxide; povidone; magnesium stearate; glycerol; mannitol; sucrose - l.c.e. sandoz 75/18.75/200 is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 150/37.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stalevo 150/37.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 150 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 40.5 mg (equivalent: carbidopa, qty 37.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stalevo 100/25/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 100 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 27 mg (equivalent: carbidopa, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

STALEVO 50/12.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

stalevo 50/12.5/200 levodopa/carbidopa (as monohydrate)/entacapone tablet bottle

sandoz pty ltd - levodopa, quantity: 50 mg; entacapone, quantity: 200 mg; carbidopa monohydrate, quantity: 13.5 mg (equivalent: carbidopa, qty 12.5 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; maize starch; mannitol; povidone; glycerol; hypromellose; polysorbate 80; iron oxide red; sucrose; titanium dioxide; iron oxide yellow - stalevo is indicated for the management of patients with parkinson's disease who are experiencing motor fluctuations.

Levodopa and Carbidopa CR Actavis Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

levodopa and carbidopa cr actavis

teva pharma (new zealand) limited - carbidopa 50mg; levodopa 200mg - modified release tablet - 200mg/50mg - active: carbidopa 50mg levodopa 200mg excipient: colloidal silicon dioxide hypromellose iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose - levodopa and carbidopa cr actavis tablets are indicated for: - idiopathic parkinson's disease - postencephalic parkinsonism - symptomatic parkinsonism (carbon monoxide or manganese intoxication) - patients with parkinson's disease or parkinsonism who are taking vitamin preparations that contain pyridoxine - to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterised by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

CENTEVO levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

centevo levodopa/carbidopa/entacapone 200 mg/50 mg/200 mg tablet bottle

teva pharma australia pty ltd - levodopa, quantity: 200 mg; carbidopa monohydrate, quantity: 54.1 mg (equivalent: carbidopa, qty 50 mg); entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; lactose; hyprolose; povidone; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; glycerol; iron oxide yellow; polysorbate 80; iron oxide red; iron oxide black - centevo (levodopa/carbidopa/entacapone) is indicated for the management of patients with parkinson?s disease who are experiencing motor fluctuations.